ATC Group: N02AA Natural opium alkaloids

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02AA in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02A Opioids
4 N02AA Natural opium alkaloids

Group N02AA contents

Code Title
N02AA01 Morphine
N02AA02 Opium
N02AA03 Hydromorphone
N02AA04 Nicomorphine
N02AA05 Oxycodone
N02AA08 Dihydrocodeine
N02AA10 Papaveretum
N02AA11
N02AA51 Morphine, combinations
N02AA53
N02AA55 Oxycodone and naloxone
N02AA56
N02AA58 Dihydrocodeine, combinations
N02AA59 Codeine, combinations excl. psycholeptics
N02AA79 Codeine, combinations with psycholeptics

Active ingredients in N02AA

Active Ingredient

Dihydrocodeine is a semisynthetic narcotic analgesic with a potency between morphine and codeine. It is also a centrally-acting anti-tussive. Dihydrocodeine works on the cough centre to lessen the incidence and intensity of coughing fits.

Hydromorphone is an agonist of mu receptors. The pharmacological actions of hydromorphone and morphine do not differ significantly. Hydromorphone and related opioids produce their major effects on the central nervous system and bowel. Hydromorphone is indicated for the relief of severe pain in cancer.

Morphine is a narcotic analgesic obtained from opium. Morphine acts as an agonist at opiate receptors in the CNS particularly Mu and to a lesser extent Kappa receptors. Mu receptors are thought to mediate supraspinal analgesia, respiratory depression and euphoria, and Kappa receptors, spinal analgesia, miosis and sedation.

Nicomorphine is the 3,6-dinicotinate ester of morphine. Nicomorphine is a strong opioid agonist analgesic two to three times as potent as morphine with a side effect profile similar to that of dihydromorphine, morphine, and diamorphine. The 3,6-diesters of morphine are drugs with more rapid and complete central nervous system penetration due to increased lipid solubility and other structural considerations.

 Opium

Opium alkaloids (opioids and isoquinoline derivatives) induce constipation, euphoria, analgesia and sedation dependent on the dose and derivative. The constipating effect is caused by inhibition of the intestines' peristalsis.

Oxycodone is a full opioid agonist with no antagonist properties. It has an affinity for kappa, mu and delta opioid receptors in the brain and spinal cord. Oxycodone is similar to morphine in its action. The therapeutic effect is mainly analgesic, anxiolytic, antitussive and sedative.

Oxycodone and naloxone have an affinity for kappa, mu and delta opiate receptors in the brain, spinal cord and peripheral organs (e.g. intestine). Oxycodone acts as opioid-receptor agonist at these receptors and binds to the endogenous opioid receptors in the CNS. By contrast, naloxone is a pure antagonist acting on all types of opioid receptors. Naloxone counteracts opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

Oxymorphone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxymorphone is analgesia. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.

Related product monographs

Document Type Information Source  
 DILAUDID Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 JURNISTA Prolonged-release tablet MPI, EU: SmPC Marketing Authorisation Holder
 KADIAN Capsule extended-release MPI, US: SPL/PLR FDA, National Drug Code (US)
 LYNLOR Capsule, hard MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MORPHGESIC Controlled release tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MS CONTIN Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 MST CONTINUS Prolonged release granules for oral suspension MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MST CONTINUS Prolonged-release tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 OXYACT Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 OXYCONTIN Film-coated, extended release tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 OXYNORM 10 mg/ml Solution for injection or infusion MPI, EU: SmPC Υπουργείο Υγείας (CY)
 OXYNORM Capsule, hard MPI, EU: SmPC Υπουργείο Υγείας (CY)
 OXYNORM Concentrate oral solution MPI, EU: SmPC Υπουργείο Υγείας (CY)
 PALLADONE Prolonged release capsule MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 PALLADONE Solution for injection or infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 PARACODIN Oral drops, solution MPI, EU: SmPC Health Products Regulatory Authority (IE)
 PARACODIN Syrup MPI, EU: SmPC Health Products Regulatory Authority (IE)
 PARACODIN Tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 SEVREDOL Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 STATEX Oral Drops, Suppositories, Oral Syrup, Tablets MPI, CA: SPM Health Products and Food Branch (CA)
 TARGIN Prolonged-release tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 TARGINACT Prolonged release tablet MPI, Generic Health Products Regulatory Authority (ZA)
 TARGINACT Prolonged-release tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)